英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
honorabilis查看　honorabilis　在百度字典中的解释百度英翻中〔查看〕
honorabilis查看　honorabilis　在Google字典中的解释Google英翻中〔查看〕
honorabilis查看　honorabilis　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • AMG 410 and the Next Frontier in KRAS-Driven Cancer Treatment
    Unlike covalent, mutation-specific agents, AMG 410 is a non-covalent, state-independent inhibitor capable of targeting multiple KRAS mutations, including G12D, G12V, and G13D It binds both GTP- and GDP-bound KRAS, offering broad-spectrum suppression of oncogenic signaling
  • AMG410 | KRAS Inhibitor - MedChemExpress
    AMG410 is a dual GTP (on)- and GDP (off)-state inhibitor (K d (GDP-state) of 1 nM; K d (GTP-state) of 22 nM) AMG410 blocks KRAS signaling in a cycling state-independent manner and also blocks proliferation in wildtype KRAS-amplified tumor cells AMG410 can be used for the study of colorectal, pancreatic, and lung cancers For research use only
  • Abstract ND01: AMG 410: An H NRAS-sparing pan-KRAS inhibitor with dual . . .
    Leveraging insights from KRAS G12Ci, we here report the structure- and property-based design of a non-covalent “pan-KRAS” inhibitor, AMG 410, which binds to the most clinically relevant KRAS mutants (e g , G12D, G12V, G13D; IC 50 values = 1-4 nM) via the same allosteric pocket employed by approved KRAS G12C inhibitors
  • AMG410 | Non-covalent pan-KRAS inhibitor | Antitumor | TargetMol
    AMG410 is a non-covalent pan-KRAS inhibitor that demonstrates potent activity against several clinically relevant KRAS mutations, including G12D, G12V, and G13D, with IC₅₀ values ranging from 1 to 4 nM
  • New Drugs on the Horizon sessions provide first look at 12 new . . .
    Brian A Lanman, PhD, of Amgen, shared AMG 410, a pan-KRAS ON OFF inhibitor capable of targeting a wide array of KRAS mutations and amplifications, but not HRAS or NRAS In pancreatic xenograft models, AMG 410 showed significant efficacy alone and in combination with EGFR and PD-1 therapies
  • AMG 410 - Drug Targets, Indications, Patents - Synapse
    AMG 410: a KRAS inhibitors Drug, Initially developed by Amgen, Inc , Now, its global highest R D status is Preclinical, Mechanism: KRAS inhibitors(GTPase KRas inhibitors), Therapeutic Areas: Neoplasms, Active Indication: KRAS mutation-related tumors, Active Org : Amgen, Inc
  • Product Data Sheet - MedChemExpress
    ND01 - AMG 410: An H NRAS-sparing pan-KRAS inhibitor with dual GTP(on) GDP(off)-state activity for the treatment of diverse KRAS-mutant tumors Caution: Product has not been fully validated for medical applications For research use only
  • AMG410 (AMG-410) | CAS 3040175-17-2 | AbMole BioScience | AMG410 Price
    AMG410 is a non-covalent and selective pan-KRAS inhibitor with IC50 values of 1-4 nM for KRAS G12D, KRAS G12V, and KRAS G13D AMG410 is a dual GTP (on)- and GDP (off)-state inhibitor (Kd (GDP-state) of 1 nM; Kd (GTP-state) of 22 nM)
  • AMG410 | KRAS inhibitor | Probechem Biochemicals
    AMG410 is a potent, non-covalent and selective pan-KRAS inhibitor with IC50 values of 1-4 nM for KRAS G12D, KRAS G12V, and KRAS G13D,> 100-fold selectivity against both HRAS and NRAS
  • AMG 410 Amgen - LARVOL DELTA - delta. larvol. com
    AMG 410: An H NRAS-sparing pan-KRAS inhibitor with dual GTP(on) GDP(off)-state activity for the treatment of diverse KRAS-mutant tumors (AACR 2025) - "Approved inhibitors (sotorasib adagrasib) are only effective for tumors harboring the KRAS G12C mutation, however, and major unmet need remains for the larger population of patients (~140k





中文字典-英文字典  2005-2009